In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the American Academy of Neurology (AAN 2023), held in Boston, Massachusetts, from 22-27 April 2023.
The topics discussed are:
- Teriflunomide prevents conversion to MS in patients with RIS
In people with radiologically isolated syndrome, treatment with teriflunomide resulted in a 62% risk reduction compared with a placebo for a first clinical event related to the CNS. These outcomes add evidence for the benefit of early intervention with disease-modifying treatment in the demyelinating spectrum of multiple sclerosis. - First-ever ALS platform trial reports on outcomes of 4 treatments
The HEALEY ALS Platform trial accelerates the path to new therapies for amyotrophic lateral sclerosis by testing multiple investigational products concurrently and sequentially. Results of 4 regimens which had concluded the RCT period were shared at the AAN 2023 meeting: zilucoplan, verdiperstat, CNM-Au8, and pridopidine. - Atogepant helps prevent treatment-resistant episodic migraine
In the randomised, double-blind, placebo-controlled ELEVATE trial, atogepant 60 mg once daily was effective in preventing difficult-to-treat episodic migraine in patients who had previously failed between 2 and 4 classes of oral preventive migraine medications. Atogepant was safe and well-tolerated. - Spinal cord stimulation eases painful diabetic neuropathy
In a randomised controlled trial, 10 kHz spinal cord stimulation provides durable pain relief to patients with painful diabetic neuropathy. The safety of the device was acceptable. Treatment effects at 6 months were maintained at 24 months. - Donanemab shows rapid and deep plaque clearance in early Alzheimer’s disease
More patients with early symptomatic Alzheimer’s disease (AD) reached amyloid clearance and plaque reductions at 6 months with donanemab than with aducanumab in the TRAILBLAZER-ALZ 4 study. Donanemab’s rapid and deep plaque clearance was associated with improvements in plasma phospho-tau, a key biomarker of AD. - Ravulizumab effective in AQP4+ NMOSD
In the open-label, phase 3 trial CHAMPION-NMOSD, ravulizumab significantly lowered the risk of relapse and worsening of the Hauser Ambulation Index (HAI) score versus placebo in participants with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD).
Enjoy listening!
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Letter from the Editor Next Article
EBMT 2023 Highlights Podcast »
« Letter from the Editor Next Article
EBMT 2023 Highlights Podcast »
Table of Contents: AAN 2023
Featured articles
Letter from the Editor
Positive results for hereditary transthyretin-mediated amyloid polyneuropathy
Infectious Diseases
Allogenic T-cell-based immunotherapy for PML in development
Cognitive Impairment and Dementia
Lecanemab may slow decline of cognition and function in Alzheimer’s Disease
Donanemab shows rapid and deep plaque clearance in early Alzheimer’s Disease
Epilepsy
Seizure forecasting and detection with wearable devices are feasible
Encouraging first results of GABAergic interneurons implants for focal epilepsy
Headache and Migraine
Lecture on migraine: from the prodromal phase to future paradigm shifts
Zavegepant nasal spray exhibits good efficacy and safety in acute migraine
A vaccine as a potentially safe and effective immunotherapy against CGRP
Multiple Sclerosis
Teriflunomide prevents conversion to MS in patients with RIS
Gold nanocrystals may be effective as adjunctive MS therapy
Muscle and Neuro-Muscular Disorders
First-ever ALS platform trial reports on outcomes of 4 treatments
Pridopidine for Huntington’s disease fails to meet the primary endpoint
Parkinson's Disease
Continuous levodopa/carbidopa infusion shows favourable safety and efficacy
Unilateral right STN-DBS improves verbal fluency
Stroke
Harnessing the microbiome as a possible stroke treatment
Patients with a large core infarct benefit from thrombectomy
Miscellaneous
Artificial intelligence applications in neurology: seize the moment
Spinal cord stimulation eases painful diabetic neuropathy
EVT improves functional outcomes in Chinese patients with BAO
Severe sleep apnoea associated with white matter hyperintensities
Related Articles
October 30, 2022
In the spotlight: Cancer trends in obstructive sleep apnoea
October 29, 2020
Physical activity improves AHI in sleep apnoea patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com